Loading stock data…
Sol-Gel Technologies Ltd (SLGL)
$69.37-0.15 (-0.22%)
Market ClosedLast close Sep 8
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sol-Gel Technologies Ltd. in the Healthcare sector is trading at $69.37 with a market capitalization of $238M. Wall Street consensus targets $196.67 (3 analysts), implying a +183.5% move over the next 12 months. The stock is currently 29% below its 52-week high of $97.97, remaining 0.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 27 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +183.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 27) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $108,000↓ | $696,000↑ | $400,000↓ | $17.26M↑ | $1.03M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.85M↓ | -$3.41M↑ | -$6.29M↓ | $11.23M↑ | -$9.07M |
| Net Income | -$3.73M↓ | -$2.99M↑ | -$5.94M↓ | $11.61M↑ | -$8.81M |
Peer Comparison
JNJUNHPFE
Fundamentals
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The compan...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$237.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.03%
Volume
Today's trading volume
38,593
Recent News
MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates
MeiraGTx (MGTX) delivered earnings and revenue surprises of +538.46% and +20,637.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates
Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -15.87% and -120.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals (SUPN) Matches Q2 Earnings Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 0.00% and +6.84%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Sol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue Estimates
SolGel Technologies (SLGL) delivered earnings and revenue surprises of +28.80% and -88.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
US Equity Indexes Fall Amid Uncertainty Over US-Iran Truce Talks
US equity indexes fell on Tuesday as oil prices continued to rise amid uncertainty surrounding truce